Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects

Xintela (XINT) announces today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of the company’s stem cell product XSTEM® for the treatment and regeneration of skin defects, including difficult-to-heal (chronic) wounds. The patent, US 12,599,633, issues today and protects XSTEM in the United States until 7 June […]

Xintela publication on EQSTEM treatment of horses in a preclinical osteoarthritis study awarded best basic science paper

The results from Xintela’s preclinical EQSTEM® study in horses with post-traumatic osteoarthritis (OA) has previously been published in the scientific journal Cartilage. The results show less pain and less cartilage damage after treatment with the stem cell product EQSTEM, indicating a disease modifying effect of EQSTEM. The publication has now been awarded best basic science […]

Xintela completes clinical study with XSTEM in difficult-to-heal leg ulcers

Xintela (XINT) announces that the company’s clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers has been completed with the last follow-up visit for the last patient. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s Phase I/IIa clinical study in patients […]

Last patient dosed in Xintela’s clinical study on difficult-to-heal leg ulcers

Xintela (XINT) announces that the last patient has been dosed in the company’s clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s ongoing Phase I/IIa clinical study in patients with difficult-to-heal venous leg […]

Xintela announces subsidiary Targinta collaboration with MSK Therapeutics Accelerator

Xintela (XINT) announces that Xintela’s oncology subsidiary, Targinta AB, has today initiated a collaboration with Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator in New York, USA, for development of its integrin α10β1 antibody therapeutic in patients with aggressive sarcoma. Under the collaboration, Targinta will produce antibodies targeting integrin α10β1 and complete preclinical development work […]

Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study

The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pain, improved joint function, and improvements in bone and cartilage structure. This confirms a sustained treatment effect in knee osteoarthritis and supports a disease-modifying effect of […]

Xintela strengthens management team with Peter Ekolind as COO & VP Commercial Manufacturing

Xintela announces the appointment of Peter Ekolind as Chief Operating Officer (COO) and Vice President Commercial Manufacturing. Peter started his position on August 18, 2025.With this recruitment, Xintela reinforces its focus on the company’s GMP manufacturing facility, a strategic asset for the commercial production of cell therapy products as well as for the supply of […]

Xintela completes clinical study with XSTEM in knee osteoarthritis

Xintela’s clinical study with XSTEM in knee osteoarthritis has been completed with the last follow-up visit for the last patient. Xintela previously communicated positive interim results up to 18 months after treatment and now completed the collection of 24-months data for the highest dose level. The final results of the study are planned to be reported […]

Xintela AB changes Certified Adviser to Tapper Partners AB

Xintela AB announces today that the company is changing its Certified Adviser to Tapper Partners AB. Xintela AB has entered into an agreement with Tapper Partners AB regarding the role as Certified Adviser. Tapper Partners AB will assume the role of Certified Adviser on August 15, 2025. Until then, DNB Carnegie Investment Bank AB will […]